Fort Washington Investment Advisors Inc. OH lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 87.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,792 shares of the healthcare product maker’s stock after selling 1,667,465 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Abbott Laboratories were worth $11,122,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Heritage Trust Co lifted its position in Abbott Laboratories by 10.1% in the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares in the last quarter. Winfield Associates Inc. lifted its position in Abbott Laboratories by 3.9% in the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. lifted its position in Abbott Laboratories by 17.7% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares in the last quarter. JFS Wealth Advisors LLC lifted its position in Abbott Laboratories by 349.0% in the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 2,094 shares in the last quarter. Finally, Motco lifted its position in Abbott Laboratories by 213.7% in the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 1,962 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors.

Shares of Abbott Laboratories (ABT) opened at $54.79 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a one year low of $37.42 and a one year high of $56.69. The company has a market cap of $95,228.27, a PE ratio of 22.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter last year, the business posted $0.59 EPS. Abbott Laboratories’s quarterly revenue was up 28.8% compared to the same quarter last year. equities research analysts forecast that Abbott Laboratories will post 2.49 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were paid a dividend of $0.265 per share. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.93%. Abbott Laboratories’s payout ratio is currently 83.47%.

In other news, insider Brian J. Blaser sold 23,866 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $55.55, for a total transaction of $1,325,756.30. Following the completion of the sale, the insider now owns 146,387 shares in the company, valued at approximately $8,131,797.85. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alejandro D. Wellisch sold 2,153 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the sale, the insider now owns 10,256 shares of the company’s stock, valued at approximately $572,900.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 311,127 shares of company stock valued at $16,958,579. 0.76% of the stock is currently owned by company insiders.

Several equities analysts recently weighed in on the stock. Cowen reaffirmed a “buy” rating and issued a $55.00 price target on shares of Abbott Laboratories in a research report on Thursday, August 17th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Barclays raised their price target on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Citigroup started coverage on shares of Abbott Laboratories in a research note on Thursday, August 17th. They issued a “neutral” rating and a $53.00 price objective for the company. Finally, ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $56.81.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/06/abbott-laboratories-abt-shares-sold-by-fort-washington-investment-advisors-inc-oh.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.